Read our Recent Headlines

August 23 Biotech Update

Well, as much as I thought my routine would return to normal next week, we learned the schools are not going to open until September 6th at the earliest meaning.

August 22 Biotech Update

The sector is doing well on the consummation of the long courtship of MDVN. I will be back with my commentary this week but am still not quite back to.

August 18 Biotech Update

I am sorry to not have been writing but it has been busy here in Louisiana with the floods. My house was close to the leading each (about 50 yards).

August 11 Biotech Update

We now seem to be stuck in a small rut with the near term trend being slightly negative and nothing really to break it. Perhaps value investors step in at.

August 10 Biotech Update

The market continues to consolidate and I expect this trend to continue over the near term. If I am correct that this is simply a consolidation in a new bull.

August 9 Biotech Update

We certainly have seen some recent under-performance by the sector but given recent strength and run of bad news (trial failures, secondaries, and so on) this is not stunning. So.

August 8 Biotech Update

The sector seems to be struggling a little but it would not be stunning to see some underperformance and consolidation after the recent run. We continue to get earnings headlines.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!